Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, has settled allegations with 36 states and the District of Columbia regarding allegations related to promotional and marketing practices for its antipsychotic drug Risperdal.   The company will pay approximately $181 million as part of a consent decree to resolve state consumer protection law claims in the 36 states and the District of Columbia. The company agreed to the settlement to resolve the concerns and to avoid unnecessary ex...